Department of Radiation Oncology, GROW Research Institute, Maastricht, The Netherlands.
Radiother Oncol. 2011 May;99(2):137-41. doi: 10.1016/j.radonc.2011.04.004. Epub 2011 May 14.
Recent literature suggests that tumor cells and areas within tumors with a high initial FDG uptake might be more resistant to (chemo)radiotherapy ((C)RT). This study was undertaken to test this hypothesis in rectal cancer using rigid and non-rigid image registration.
Twenty-eight patients, diagnosed with locally advanced rectal cancer and referred for pre-operative treatment with CRT were included in this study. All patients underwent FDG-PET-CT imaging prior to and after CRT. Rigid and non-rigid image registration was performed to compensate organ deformations between the pre- and post-treatment PET-CT scans. The tumor was contoured on both PET-scans using SUV iso-contouring based on the SBR-method. The voxels with residual increased FDG uptake were studied and correlated to their pre-treatment FDG uptake level. Two SUV-volume-histograms were made based on the pre-treatment PET-data, one for the voxels within the pre-treatment tumor PET-based iso-contour and one for the voxels within the PET-based iso-contour of the residual tumor non-rigidly registered onto the pre-treatment scan.
For the voxels with a pre-treatment FDG uptake of >50% of SUV(max), 70.6±5.6% of the voxels were still metabolic active in the residual tumor, whereas for voxels with an FDG uptake of <50% of SUV(max) only 51.1±6.7% were present in the metabolic active residual tumor.
This study presents areas in rectal tumors with an initially high FDG uptake to be most likely to show residual disease after CRT. This could indicate a higher (C)RT-resistance for tumor regions with a high FDG uptake prior to treatment.
最近的文献表明,初始 FDG 摄取量高的肿瘤细胞和肿瘤内区域可能对(放)化疗(C)RT 更具抵抗力。本研究旨在使用刚性和非刚性图像配准来测试直肠癌中的这一假设。
本研究纳入了 28 例诊断为局部晚期直肠癌并接受术前 CRT 治疗的患者。所有患者在 CRT 前后均进行了 FDG-PET-CT 成像。进行刚性和非刚性图像配准,以补偿治疗前后 PET-CT 扫描之间的器官变形。使用基于 SBR 方法的 SUV 等浓度线在两次 PET 扫描上对肿瘤进行轮廓勾画。研究了具有残留 FDG 摄取增加的体素,并将其与治疗前的 FDG 摄取水平相关联。根据预处理 PET 数据制作了两个 SUV 体积直方图,一个是预处理肿瘤 PET 基于等浓度线内的体素,另一个是非刚性配准到预处理扫描的残留肿瘤的 PET 基于等浓度线内的体素。
对于治疗前 FDG 摄取>50% SUV(max)的体素,在残留肿瘤中仍有 70.6±5.6%的体素具有代谢活性,而对于 FDG 摄取<50% SUV(max)的体素,只有 51.1±6.7%存在于代谢活性残留肿瘤中。
本研究表明,初始 FDG 摄取量较高的直肠肿瘤区域在 CRT 后最有可能出现残留疾病。这可能表明治疗前 FDG 摄取量较高的肿瘤区域对(放)化疗(C)RT 具有更高的抵抗力。